A Phase 2a, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of AL-3778 in Combination With Peginterferon Alpha-2a in Treatment Naïve Chronic Hepatitis B Subjects Who Are HBeAg-positive

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 21 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NVR 3778 (Primary) ; Peginterferon alfa-2a
Indications Hepatitis B
Focus Therapeutic Use
Sponsors Alios BioPharma

Most Recent Events

13 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
15 Aug 2017 Planned End Date changed from 30 Dec 2018 to 15 Feb 2019.
15 Aug 2017 Planned primary completion date changed from 30 Dec 2018 to 15 Feb 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight